Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Kidney Int. 2011 Aug 10;80(11):1198–1211. doi: 10.1038/ki.2011.261

Figure 10. Splenectomy transiently decreases HMGB1 and renders anti-HMGB1 ineffective in treating CKD-sepsis.

Figure 10

CD-1 mice were subjected to 5/6 Nx, and after 4 weeks, splenectomy was performed at day 0. Serum HMGB1 (A) was measured in 5/6 Nx controls (black squares) or 5/6 Nx-splenectomy (white squares). Loss of CKD-sepsis-stimulated serum HMGB1 (B): four weeks after 5/6 Nx mice were subjected to splenectomy (gray bar), and after three days sham surgery (white bar) or CLP (black bar, gray bar) was performed, and serum HMGB1 was measured after 18 h. Outcomes of CKD-sepsis (see also Supplemental Fig 4): four weeks after 5/6 Nx mice were subjected to splenectomy (day 0), and after three days sham surgery (white bars) or CLP (black bars, gray bars) was performed, followed by administration of control IgG (black bars) or anti-HMGB1 (gray bars) 6 h later, then measurement of Scr (C), ALT (D), or TNFα (E) at 18 h.